Home > Compound List > Compound details
274901-16-5 molecular structure
click picture or here to close

(2S)-1-{2-[(3-hydroxyadamantan-1-yl)amino]acetyl}pyrrolidine-2-carbonitrile

ChemBase ID: 4392
Molecular Formular: C17H25N3O2
Molecular Mass: 303.3993
Monoisotopic Mass: 303.19467706
SMILES and InChIs

SMILES:
OC12CC3(NCC(=O)N4[C@@H](CCC4)C#N)CC(C1)CC(C3)C2
Canonical SMILES:
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(C1)CC(C2)(C3)O
InChI:
InChI=1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12?,13?,14-,16?,17?/m0/s1
InChIKey:
SYOKIDBDQMKNDQ-XWTIBIIYSA-N

Cite this record

CBID:4392 http://www.chembase.cn/molecule-4392.html

Collapse All Expand All

NAMES AND DATABASE IDS

NAMES AND DATABASE IDS

Names Database IDs
IUPAC name
(2S)-1-{2-[(3-hydroxyadamantan-1-yl)amino]acetyl}pyrrolidine-2-carbonitrile
IUPAC Traditional name
(2S)-1-{2-[(3-hydroxyadamantan-1-yl)amino]acetyl}pyrrolidine-2-carbonitrile
vildagliptin
EQUA
Brand Name
Galvus
Synonyms
Zomelis
Vildagliptin
NVP-LAF-237
LAF237
LAF 237
EQUA
Galvus
Jalra
NVP-LAF237
Xiliarx
Vildagliptin
CAS Number
274901-16-5
MDL Number
MFCD08275142
PubChem SID
160967824
99443227
PubChem CID
6918537

CALCULATED PROPERTIES

CALCULATED PROPERTIES

JChem ALOGPS 2.1
Acid pKa 14.705235  H Acceptors
H Donor LogD (pH = 5.5) -3.2804537 
LogD (pH = 7.4) -1.8509002  Log P -0.21739453 
Molar Refractivity 81.9991 cm3 Polarizability 32.339184 Å3
Polar Surface Area 76.36 Å2 Rotatable Bonds
Lipinski's Rule of Five true 
Log P 1.12  LOG S -2.24 
Solubility (Water) 1.75e+00 g/l 

PROPERTIES

PROPERTIES

Safety Information Pharmacology Properties Product Information Bioassay(PubChem)
Storage Warning
IRRITANT expand Show data source
MSDS Link
Download expand Show data source
TSCA Listed
false expand Show data source
Mechanism of Action
Dipeptidyl peptidase-4 (DPP-4) inhibitor expand Show data source
Purity
95% expand Show data source
95+% expand Show data source
97% expand Show data source
Application(s)
Anti-hyperglycemic agent expand Show data source

DETAILS

DETAILS

DrugBank DrugBank
DrugBank - DB04876 external link
Item Information
Drug Groups approved; investigational
Description Vildagliptin, previously identified as LAF237, is a new oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucaon release by the alpha cells of the islets of Langerhans in the pancreas. It is currently in clinical trials in the U.S. and has been shown to reduce hyperglycemia in type 2 diabetes mellitus. While the drug is still not approved for use in the US, it was approved in Feb 2008 by European Medicines Agency for use within the EU and is listed on the Australian PBS with certain restrictions.
Indication Used to reduce hyperglycemia in type 2 diabetes mellitus.
Pharmacology Vildagliptin belongs to a class of orally active antidiabetic drugs (DPP-IV inhibitors) that appear to have multiple functional benefits beyond simple blood-glucose control. One of these is a potential protective effect on pancreatic beta cells, which deteriorate in diabetes. Vildagliptin appears to be safe, very well tolerated, and efficacious. Following a meal, gut incretin hormones are released. The most important incretin hormones are GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). These hormones, secreted in the human small intestine, are responsible for insulin release due to increased glucose levels. In contrast to agents that promote insulin secretion via glucose-independent mechanisms, GLP-1's dependence on glucose concentration is considered beneficial due to a lower risk of hypoglycemia. GLP-1 also inhibits glucagon secretion and increases beta cell mass by stimulating proliferation and neogenesis. However, the clinical utility of GLP-1 is limited by its short half-life (2 minutes). GLP-1 is rapidly degraded by the proteolytic enzyme DPP-IV. To enhance GLP-1 activity, inhibition of the DPP-IV enzyme is emerging as a novel therapeutic approach in the treatment of diabetes. Administration of vildagliptin enhances GLP-1's ability to produce insulin in response to elevated concentrations of blood glucose, inhibit the release of glucagon following meals, slow the rate of nutrient absorption into the bloodstream, slow the rate of gastric emptying, and reduce food intake.
Affected Organisms
Humans and other mammals
Absorption Rapidly absorbed following oral administration with an oral bioavailability of greater than 90%.
Half Life The elimination half-life is approximately 90 minutes.
Protein Binding 9.3%
References
Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, He YL, Darland C, Holst JJ, Deacon CF, Cusi K, Mari A, Foley JE, DeFronzo RA: The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab. 2007 Apr;92(4):1249-55. Epub 2007 Jan 23. [Pubmed]
External Links
Wikipedia

REFERENCES

REFERENCES

From Suppliers Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
  • • Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, He YL, Darland C, Holst JJ, Deacon CF, Cusi K, Mari A, Foley JE, DeFronzo RA: The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab. 2007 Apr;92(4):1249-55. Epub 2007 Jan 23. Pubmed
  • • 1. Ahre'n, B; Landin-Olsson, M; Jansson, PA; Svensson, M; Holmes, D; Schweizer, A (2004). "Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels
  • • in type 2 diabetes". The Journal of clinical endocrinology and metabolism 89 (5): 2078?4.
  • • 2. Mentlein, R; Gallwitz, B; Schmidt, WE (1993). "Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible
  • •  for their degradation in human serum". European journal of biochemistry / FEBS 214 (3): 829?5.
  • Searching...Please wait...

PATENTS

PATENTS

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

INTERNET

INTERNET

Baidu iconBaidu google iconGoogle